UCL Institute of Ophthalmology


DARC Phase I Clinical Trial for Early Diagnosis of Neurodegeneration

This Phase I, Storer Design, Open-label, Cross-sectional, Single Site Trial of ANX776 in Healthy Volunteers and Glaucoma patients was completed in 2017. The results were published in 2017 and showed the use of DARC in humans for the first time was safe, well-tolerated with potential as a biomarker.

  1.  Cordeiro MF, Normando EM, Cardoso MJ, Miodragovic S, Jeylani S, Davis BM, Guo L, Ourselin S, A'Hern R, Bloom PA. Real-time imaging of single neuronal cell apoptosis in patients with glaucoma Brain. 2017 Jun 1;140(6):1757-1767.